Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Change in Accured Expenses (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Change in Accured Expenses for 13 consecutive years, with $29991.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 30.01% to $29991.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $160451.0, a 256.3% increase, with the full-year FY2025 number at $173312.0, up 768.91% from a year prior.
  • Change in Accured Expenses was $29991.0 for Q4 2025 at Regen BioPharma, down from $63981.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $102107.0 in Q1 2021 to a low of -$17936.0 in Q1 2024.
  • A 5-year average of $32384.6 and a median of $25820.5 in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 248.42% in 2024, then surged 2396.33% in 2025.
  • Regen BioPharma's Change in Accured Expenses stood at $6036.0 in 2021, then soared by 187.59% to $17359.0 in 2022, then grew by 2.34% to $17765.0 in 2023, then surged by 141.22% to $42852.0 in 2024, then tumbled by 30.01% to $29991.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Change in Accured Expenses are $29991.0 (Q4 2025), $63981.0 (Q3 2025), and $21650.0 (Q2 2025).